Parkinson’s disease patients generally need to take L-dopa(Levodopa) for a long time to ameliorate symptoms of the disease. About 90% of patients who have been taking L-dopa(Levodopa) for 10 years or longer develop dyskinesia in Parkinson’s disease, a kind of movement disorder. However there is no appropriate drug to treat this condition.
 

Bukwang Pharmaceutical strategically acquired 100% shares of Contera Pharma, a CNS-focused Danish bioventure company based in Copenhagen, to develop JM-010, an innovative treatment of dyskinesia in Parkinson's disease patients.
 

Following completion of clinical Proof of Concept Study and Phase I PK Study in South Africa and Germany, respectively. Late Phase II Study in both United States and E.U. including Germany, France, Spain, Italy, Republic of Korea is currently undergoing.
 

In 2017, ‘JM-010’ received orphan drug designation from Korea Ministry of Food and Drug Safety.
 

JM-010 is an innovative drug that holds a novel mechanism of action as fixed dose combination of two safe marketed products in a proprietary formulation and acts on dyskinesia in Parkinson's disease by inhibiting neurotransmitters in pre-synaptic neurons.